, a bio/informatics shared resource is still "open for business" - Visit the CDS website


Marta Crispens
Faculty Member
Last active: 3/10/2014

Ovarian cancer, version 2.2013.

Morgan RJ, Alvarez RD, Armstrong DK, Burger RA, Chen LM, Copeland L, Crispens MA, Gershenson DM, Gray HJ, Hakam A, Havrilesky LJ, Johnston C, Lele S, Martin L, Matulonis UA, O'Malley DM, Penson RT, Powell MA, Remmenga SW, Sabbatini P, Santoso JT, Schink JC, Teng N, Werner TL, Dwyer MA, Hughes M, National comprehensive cancer networks
J Natl Compr Canc Netw. 2013 11 (10): 1199-209

PMID: 24142821 · DOI:10.6004/jnccn.2013.0142

These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.

MeSH Terms (4)

Female Humans Ovarian Neoplasms Recurrence

Connections (1)

This publication is referenced by other Labnodes entities:

Links